Xi I Chen

6426347, Jul 30, 2002

Dec 13, 2000

09/736566

Andrew Thurkauf - Danbury CT
Xi Chen - Clinton CT

Neurogen Corporation - Branford CT

C07D295073

51425503, 544392

Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R is halogen or C -C alkyl; and R and R are the same or different and represent hydrogen, halogen, C -C alkyl, C -C alkoxy, alkylthio, hydroxy, amino, mono(C -C )alkylamino, di(C -C )alkylamino, or R and R together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

6429312, Aug 6, 2002

Mar 19, 2001

09/812199

Jun Yuan - Clinton CT
Xi Chen - New Haven CT

Neurogen Corporation - Branford CT

C07D40914

544295, 544363, 544364, 544375, 544376, 544333, 5462811, 546146, 546175, 546194, 546202, 546256, 549 43, 549 48

Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof, wherein: R , R , R , R are the same or different and represent hydrogen, C -C alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C -C alkoxy, âO CRâ, âNHCORâ, âCORâ, âSO Râ, where Râ is C -C alkyl and wherein m is 0, 1 or 2; or R , R , R , R independently represent âCONRâRâ, or âNRâRâ where Râ and Râ independently represent hydrogen or C -C alkyl; R is hydrogen or C -C alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimers disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

6656943, Dec 2, 2003

Jun 28, 2002

10/186235

Andrew Thurkauf - Danbury CT
Xi Chen - Clinton CT

Neurogen Corporation - Branford CT

A61K 31495

51425503, 544392

Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: R is halogen or C -C alkyl; and R and R are the same or different and represent hydrogen, halogen, C -C alkyl, C -C alkoxy, alkylthio, hydroxy, amino, mono(C -C )alkylamino, di(C -C )alkylamino, or R and R together represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

7101887, Sep 5, 2006

Jun 27, 2005

11/167735

Andrew Thurkauf - Danbury CT, US
Xi Chen - Clinton CT, US

Neurogen Corporation - Branford CT

A61K 31/495
C07D 295/076

51425503, 544392

Disclosed are compounds of the formula:.

7183300, Feb 27, 2007

Nov 10, 2005

11/271437

Michael F. Summers - Ellicott City MD, US
Atul Agarwal - Hamden CT, US
Xi Chen - Killingworth CT, US
Milind Deshpande - Madison CT, US

A61K 31/4245
A61K 31/426
A61K 31/341
C07D 271/08
C07D 277/48
C07D 307/54

514364, 514377, 514461, 548125, 548196, 549473

Substituted aryl aminomethyl thiazole ureas and analogues thereof that act as inhibitors of viral capsid formation, including HIV capsid formation, are provided here. Generally the virus capsid formation inhibitors described herein are compounds of Formula I.

7230159, Jun 12, 2007

Mar 5, 2003

10/505744

Tesfaye Mengiste - West Lafayette IN, US
Xi Chen - Research Triangle Park NC, US
John Salmeron - Research Triangle Park NC, US
Robert Dietrich - Research Triangle Park NC, US

Syngenta Participations AG - Basel

C12N 15/82
C12N 15/09
A01H 5/00

800279, 800278, 800298, 536 241, 4353201, 435468

The present invention pertains to an isolated promoter sequence from BOSI gene encoding a protein for biotic and abiotic stress tolerance. Also, the invention relates to recombinant vectors, expression cassettes, host cells, plants or progeny thereof comprising nucleic acid molecules operably linked to said promoter.

20040083447, Apr 29, 2004

Sep 22, 2003

10/667821

Andrew Thurkauf - Danbury CT, US
Xi Chen - Clinton CT, US

Neurogen Corporation, A Corporation of the State of Delaware - Branford CT

G06F009/44

717/100000, 717/105000

Disclosed are compounds of the formula: or the pharmaceutically acceptable addition salts thereof wherein: Ris halogen or C-Calkyl; and Rand Rare the same or different and represent hydrogen, halogen, C-Calkyl, C-Calkoxy, alkylthio, hydroxy, amino, mono(C-C)alkylamino, di(C-C)alkylamino, or Rand Rtogether represent a 4 carbon alkenylene moiety that together with the phenyl ring to which they are attached form a naphthyl moiety, which compounds are useful in the treatment of neuropsycological diseases such as schizophrenia, psychotic depression and mania.

20060100225, May 11, 2006

Mar 23, 2005

11/088276

Xi Chen - Killingworth CT, US
Andrew Thurkauf - Ridgefield CT, US
Shirley Louise-May - Guilford CT, US

A61K 31/513
A61K 31/505
C07D 239/32

514269000, 514275000, 544320000, 544330000

Compounds of Formula 1, and pharmaceutically acceptable forms thereof, are provided: wherein the variables X, Y, Z, A, R, R, R, Rand Rare defined herein. Certain compounds of Formula 1 described herein which possess potent antiviral activity. Certain compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. Pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are also provided. Methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease or disorder are disclosed. These infectious diseases include viral infections, particularly HCV infections. Methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.